Fiche centre
Columbia University Irving Medical Center
New York — United States
Essais liés23clinical trials
VilleNew Yorklocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07282587
Essais cliniques associés
23| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Focal Therapy | Cancer | À vérifier | NCT07623941 | CUIMC Focal Therapy Registry | RECRUITING |
| Obinutuzumab | SEP | Phase 2 | NCT05783596 | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | ACTIVE_NOT_RECRUITING |
| Vasopressor | Maladie coronarienne | À vérifier | NCT04682483 | CSWG — Cardiogenic Shock Working Group Registry | RECRUITING |
| IV acetaminophen | Maladie coronarienne | Phase 3 | NCT04093219 | PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients | COMPLETED |
| CK0803 | Sclérose latérale amyotrophique | Phase 1 | NCT05695521 | REGALS — Regulatory T Cells for Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING |
| anito-cel | Myasthénie | Phase 1 | NCT06626919 | Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases | RECRUITING |
| zagociguat 15mg | Accident vasculaire cérébral | Phase 2 | NCT06402123 | PRIZM — A Phase 2b Study of Zagociguat in Patients With MELAS | COMPLETED |
| Nintedanib | Myopathies | Phase 4 | NCT05799755 | MINT — Myositis Interstitial Lung Disease Nintedanib Trial | COMPLETED |
| ONC206 | Cancer | Phase 2 | NCT07282587 | Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | RECRUITING |
| Low Dose Benfotiamine | Alzheimer | Phase 2 | NCT06223360 | A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | ACTIVE_NOT_RECRUITING |
| CABA-201 | Lupus | Phase 1/2 | NCT06121297 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | RECRUITING |
| PIONEER — Prospective Natural History Study of POLG Disease | Épilepsie | À vérifier | NCT07775872 | PIONEER — Prospective Natural History Study of POLG Disease | NOT_YET_RECRUITING |
| PF-07799544 | Cancer | Phase 1 | NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | RECRUITING |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03832998 | OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine | COMPLETED |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| KITE-363 | Myasthénie | Phase 1 | NCT07304154 | HERMOSA-2 — Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment | RECRUITING |
| CC-97540 | Lupus | Phase 2 | NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | ACTIVE_NOT_RECRUITING |
| Histotripsie — HistoSonics Edison System | Cancer | À vérifier | NCT06486454 | Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) | RECRUITING |
| silevertinib in combination with temozolomide | Cancer | Phase 2 | NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | RECRUITING |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03836040 | OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| Rimegepant (PF-07899801) | Migraine | Phase 3 | NCT04743141 | Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine | RECRUITING |
| 18F-MK6240 | Alzheimer | Phase 2 | NCT07758660 | ADRC PET — Alzheimer's Disease Research Center (ADRC) PET Component Study | ENROLLING_BY_INVITATION |
| NKX019 | Lupus | Phase 1 | NCT06518668 | A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | ENROLLING_BY_INVITATION |